文献速递泌尿生殖与妇科肿瘤放疗

低中危局限期前列腺癌四分割碳离子放疗的I/II期研究

A Phase I/II Study of Ultra-Hypofractionated Carbon-ion Radiation therapy for Low- and Intermediate-Risk Localized Prostate Cancer.
PubMed 文献 · Adv Radiat Oncol · 2025-01-11

这项单中心I/II期前瞻性研究纳入60例低危或中危局限期前列腺癌患者,随机分配至1周或2周方案,碳离子放疗剂量从36 Gy逐步递增至40 Gy或44 Gy。中位随访42个月,无3级及以上胃肠或泌尿毒性,44 Gy组90天内2级泌尿毒性显著高于36-40 Gy组(P<.01)。作者认为40 Gy分4次可能兼顾疗效与毒性。

要点

  • 60例低中危前列腺癌患者接受4次碳离子放疗,中位随访42个月。
  • 无3级及以上胃肠或泌尿不良事件,未观察到剂量限制性毒性。
  • 44 Gy组90天内2级泌尿毒性显著高于36-40 Gy组(P<.01)。

核心结论

  • 40 Gy分4次碳离子放疗可能兼顾疗效与毒性。
  • 作者认为本研究结果支持进一步研究该策略的疗效。

研究设计与样本

  • 单中心I/II期前瞻性研究,纳入低危或中危局限期前列腺癌患者,风险分组依据美国国家综合癌症网络(NCCN)标准。
  • 符合条件患者按1:1随机分配至1周或2周方案,每组入组10例;若剂量限制性毒性(DLT)少于4例则逐步递增剂量。
  • 初始碳离子放疗剂量为36 Gy,后续递增至40 Gy或44 Gy;低危患者不接受雄激素剥夺治疗(ADT),中危患者接受4至8个月新辅助ADT。
  • 2018年10月至2020年10月共入组60例并完成治疗方案,中位随访42个月(范围27-59个月);低危组10例,中危组50例。

主要发现

  • 两组均未发生3级及以上胃肠或泌尿不良事件,未观察到剂量限制性毒性。
  • 碳离子放疗后90天内2级泌尿毒性发生率在44 Gy组显著高于36至40 Gy组(P < .01,Yates校正卡方检验)。
  • 碳离子放疗后3年内观察到3例生化失败。
  • 未发生临床复发或前列腺癌相关死亡。

关键数值与推荐

  • 剂量限制性毒性定义为碳离子放疗开始后90天内任何3级及以上泌尿或胃肠毒性。
  • 初始碳离子放疗剂量为36 Gy,递增剂量为40 Gy或44 Gy,均分4次。
  • 低危患者不接受ADT,中危患者接受4至8个月新辅助ADT。
  • 44 Gy组90天内2级泌尿毒性发生率显著高于36至40 Gy组(P < .01,Yates校正卡方检验)。

临床怎么用

  • 作者认为40 Gy分4次碳离子放疗可能兼顾疗效与毒性。
  • 作者认为本研究结果支持进一步研究该策略的疗效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We report herein the 3-year results of a phase I/II prospective study of 4-fraction course of carbon-ion radiation therapy (CIRT) in patients with localized prostate cancer. METHODS AND MATERIALS: The present was a single-institution, phase I/II prospective study including patients with low- or intermediate-risk prostate cancer, as defined by the National Comprehensive Cancer Network criteria. Eligible patients were randomly assigned (1:1) to a 1- or 2-week schedule. Dose-limiting toxicities (DLTs) were defined as any genitourinary (GU) or gastrointestinal (GI) toxicity grade 3 or higher within 90 days of beginning CIRT. Ten patients were enrolled in each group, and the CIRT dose was increased in a stepwise manner if there were fewer than 4 cases of DLT. The initial CIRT dose was 36 Gy, followed by 40 Gy or 44 Gy. Low-risk patients did not receive androgen deprivation therapy (ADT), whereas intermediate-risk patients received 4 to 8 months of neoadjuvant ADT. RESULTS: Between October 2018 and October 2020, 60 patients were enrolled in the present study and completed the treatment regimen. The median post-CIRT follow-up period was 42 months (range, 27-59 months). Of the 60 patients enrolled, 10 were in the low-risk group, and 50 were in the intermediate-risk group. Neither group experienced grade 3 or higher GI or GU adverse events; therefore, no dose-limiting toxicities were observed. The incidence of grade 2 GU toxicity within 90 days post CIRT was significantly higher in the 44 Gy group than in the 36 to 40 Gy group (P < .01, chi-square test with Yates correction). Biochemical failure was observed in 3 cases by 3 years post CIRT. No clinical recurrence or death because of prostate cancer occurred. CONCLUSIONS: Forty Gy in 4 fractions of CIRT may be appropriate for balancing the therapeutic effects and toxicity. Our findings support further investigations into the efficacy of this strategy.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Okonogi N, Tsuji H, Kobayashi K, et al. A Phase I/II Study of Ultra-Hypofractionated Carbon-ion Radiation therapy for Low- and Intermediate-Risk Localized Prostate Cancer. Adv Radiat Oncol. 2025. PMID: 39991117. doi:10.1016/j.adro.2024.101705

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。